Payment overview · 2025
General Payments
$365.84
22 reported records · 8 companies
Healthcare provider profile · identity verified
James L Graham, MD
Allopathic & Osteopathic Physicians|Family Medicine · TIFTON, GA · NPI 1730182106
Verified facts
What the public records show
CMS Open Payments records show James L Graham, MD received $365.84 in general payments during 2025 across 22 reported records.
Lilly USA, LLC accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.27 | 21.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $75.77 | 20.7% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.46 | 15.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $54.85 | 15.0% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.81 | 11.4% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.00 | 7.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.75 | 4.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.93 | 4.3% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $365.84 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.27 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $62.95 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $55.46 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.85 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.12 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.51 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.93 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 116 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 111 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 298 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
73 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
111 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
298 | 45 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 658 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 596 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 566 | 158 |
| Omeprazole | Omeprazole | 508 | 117 |
| Gabapentin | Gabapentin | 485 | 111 |
| Lisinopril | Lisinopril | 467 | 119 |
| Metformin Hcl | Metformin Hcl | 434 | 114 |
| Losartan Potassium | Losartan Potassium | 415 | 103 |
| Sertraline Hcl | Sertraline Hcl | 316 | 64 |
| Meloxicam | Meloxicam | 313 | 88 |
| Montelukast Sodium | Montelukast Sodium | 299 | 71 |
| Ozempic | Semaglutide | 298 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 68 |
| Pravastatin Sodium | Pravastatin Sodium | 269 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 67 |
| Potassium Chloride | Potassium Chloride | 233 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 230 | 39 |
| Lorazepam | Lorazepam | 219 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 213 | 58 |
| Tramadol Hcl | Tramadol Hcl | 193 | 53 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 190 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 188 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 185 | 72 |
| Glimepiride | Glimepiride | 178 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 145 | 42 |
| Simvastatin | Simvastatin | 145 | 40 |
| Furosemide | Furosemide | 144 | 55 |
| Trazodone Hcl | Trazodone Hcl | 140 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 130 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 28 |
| Eliquis | Apixaban | 116 | 17 |
| Allopurinol | Allopurinol | 114 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 113 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 113 | 21 |
| Mounjaro | Tirzepatide | 111 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 28 |
| Alprazolam | Alprazolam | 103 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | 18 |
| Carvedilol | Carvedilol | 102 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 28 |
| Bupropion Xl | Bupropion Hcl | 96 | 25 |
| Donepezil Hcl | Donepezil Hcl | 96 | 20 |
| Famotidine | Famotidine | 96 | 26 |
| Terazosin Hcl | Terazosin Hcl | 96 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 92 | 22 |
| Temazepam | Temazepam | 82 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 21 |
| Meclizine Hcl | Meclizine Hcl | 74 | 35 |
| Linzess | Linaclotide | 73 | 20 |
| Pregabalin | Pregabalin | 73 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 23 |
| Atenolol | Atenolol | 66 | 17 |
| Rybelsus | Semaglutide | 65 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 17 |
| Buspirone Hcl | Buspirone Hcl | 59 | 15 |
| Ondansetron Odt | Ondansetron | 59 | 22 |
| Spironolactone | Spironolactone | 59 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | 13 |
| Azithromycin | Azithromycin | 56 | 50 |
| Bumetanide | Bumetanide | 52 | suppressed |
| Glipizide | Glipizide | 52 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 27 |
| Benazepril Hcl | Benazepril Hcl | 51 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 49 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 41 |
| Jardiance | Empagliflozin | 47 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 47 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | suppressed |
| Fluconazole | Fluconazole | 43 | 24 |
| Lovastatin | Lovastatin | 42 | 11 |
| Prednisone | Prednisone | 42 | 34 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 38 |
| Celecoxib | Celecoxib | 40 | 15 |
| Ezetimibe | Ezetimibe | 40 | 11 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | 11 |
| Valsartan | Valsartan | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Novolog | Insulin Aspart | 27 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 16 |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nystatin | Nystatin | 24 | 12 |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 14 |
| Naproxen | Naproxen | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 17 |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Clotrimazole | Clotrimazole | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $365.84 · 22 records | Lilly USA, LLC | ELIQUIS, EVENITY, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error